BS_3NWQXPQV
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 84.78975032851511
- age_years
- 10.422
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.466
- DNA_REPAIR+0.207
- SPERMATOGENESIS+0.206
- MYC_TARGETS_V1+0.187
- MITOTIC_SPINDLE+0.179
- MYC_TARGETS_V2+0.113
- KRAS_SIGNALING_DN+0.037
- PANCREAS_BETA_CELLS-0.010
- UNFOLDED_PROTEIN_RESPONSE-0.123
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.639
- INTERFERON_GAMMA_RESPONSE-0.636
- TNFA_SIGNALING_VIA_NFKB-0.576
- INFLAMMATORY_RESPONSE-0.567
- IL6_JAK_STAT3_SIGNALING-0.556
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.552
- NOTCH_SIGNALING-0.543
- ANGIOGENESIS-0.534
- ALLOGRAFT_REJECTION-0.528
- CHOLESTEROL_HOMEOSTASIS-0.494
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_W9AT0MR7 | medulloblastoma | — | 0.982 |
| 2 | BS_5PJCHF6V | medulloblastoma | — | 0.976 |
| 3 | BS_TE0GVDNG | medulloblastoma | — | 0.976 |
| 4 | BS_1TWCV047 | Embryonal tumors | — | 0.975 |
| 5 | BS_ERWT0ZWE | medulloblastoma | — | 0.974 |
| 6 | BS_VVFBW0YH | medulloblastoma | — | 0.972 |
| 7 | BS_4PH1MBGR | medulloblastoma | — | 0.972 |
| 8 | BS_NZ71XCG3 | medulloblastoma | — | 0.972 |
| 9 | BS_QEYPFYHD | medulloblastoma | — | 0.970 |
| 10 | BS_9PB3XH5D | medulloblastoma | — | 0.969 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.466 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.207 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.206 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.187 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.179 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.113 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.037 | Remibrutinib | — uncovered |